Search

Your search keyword '"Krenning, Eric"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Krenning, Eric" Remove constraint Author: "Krenning, Eric" Topic pancreatic neoplasms Remove constraint Topic: pancreatic neoplasms
38 results on '"Krenning, Eric"'

Search Results

1. Side-Chain Modified [ 99m Tc]Tc-DT1 Mimics: A Comparative Study in NTS 1 R-Positive Models.

2. Optimizing the Profile of [ 99m Tc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors.

3. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

4. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

5. Long-Term Efficacy, Survival, and Safety of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

6. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.

7. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.

8. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.

9. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.

10. Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

11. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.

12. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.

13. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.

14. Tumor response assessment to treatment with [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions.

15. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.

16. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

17. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

18. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.

19. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.

20. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

21. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

22. Gastroenteropancreatic neuroendocrine tumours.

23. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.

24. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

25. Rare functioning pancreatic endocrine tumors.

26. Anticancer activity of targeted proapoptotic peptides.

27. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.

28. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy.

29. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

30. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

31. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.

32. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

33. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog.

34. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

35. Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.

36. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

37. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.

38. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

Catalog

Books, media, physical & digital resources